A Global Observational Registry of Adult Patients with Homozygous Familial Hypercholesterolemia (HoFH)

Aug 04, 2020

UBC efficiently and strategically manages a global rare disease registry with rolling start-up, including mandated annual data collection and reporting.

Posted by

A long-term product exposure registry provides a more robust picture of real-world patient treatment patterns and outcomes. For our client’s rare disease global observational registry, it is critical we continue to keep the study top of mind to ensure that, year after year, study milestones are met to support the mandated FDA/EMA annual analyses. Read about our proactive and strategic management of a rare disease registry for adult patients with Homozygous Familial Hypercholesterolemia (HoFH).

Download Attachment

See all Member News